Extrait

MK7339-002 - A phase 2 study of olaparib monotherapy in participants with previously treated, homologous recombination repair mutation (HRRM) or homologous recombination deficiency (HRD) positive advanced cancer

Liens

• e-cancer.fr
• Fiche de l'U.S. National Library of Medicine (NLM), sur ClinicalTrials.gov